Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33,106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo / Placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized-Controlled Trial to Examine the Effects of a Daily Probiotic Supplement on Common Symptoms of Menopause

NCT06148714
View directory record Official record
Conditions
Menopause
Interventions
Provitalize Natural Menopause Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Maneuver Marketing
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib in Pancreatic Cancer Patients

NCT01423604
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Burbank, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers

NCT01989533
View directory record Official record
Conditions
Vaccine Response
Interventions
Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Lactobacillus Johnsonii Supplementation in Adults With T1D

NCT03961347
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
L. johnsonii Probiotic, Placebo Capsule
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 5:23 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
15
States / cities
Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 5:23 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Utility of Otosight Middle Ear Scope

NCT05641285
View directory record Official record
Conditions
Ear Infection, Middle Ear Infection, Otitis Media
Interventions
The OtoSight Middle Ear Scope
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Months to 12 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

NCT02115815
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

NCT01975935
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 27, 2026, 5:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease

NCT03971617
View directory record Official record
Conditions
Parkinson Disease
Interventions
Hydrogen, Placebo oral tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 27, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)

NCT07704840
View directory record Official record
Conditions
Post-Stroke Spasticity
Interventions
Administration of BMS-986368, Placebo
Drug
Lead sponsor
Alberto Esquenazi
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Metabolic Syndrome in PCOS: Precursors and Interventions

NCT00442689
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions
flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 27, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 27, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
View directory record Official record
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Development of NIC5-15 in the Treatment of Alzheimer's Disease

NCT00470418
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
NIC5-15, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 27, 2026, 5:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Not applicable Interventional

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

NCT00002060
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 5:23 PM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT06072482
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
Avacopan, Placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
62
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

NCT03291782
View directory record Official record
Conditions
Gout
Interventions
D-0120
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

NCT02378714
View directory record Official record
Conditions
Nicotine Dependence, Major Depressive Disorder
Interventions
Varenicline, BASC, Standard treatment
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Vabicaserin in Subjects With Schizophrenia

NCT00563706
View directory record Official record
Conditions
Schizophrenia
Interventions
vabicaserin, risperidone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Opioid Challenge Study

NCT02611752
View directory record Official record
Conditions
Moderate or Severe Opioid Use Disorder
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Overland Park, Kansas • Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 27, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

NCT02104947
View directory record Official record
Conditions
Hemorrhage
Interventions
idarucizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Loma Linda, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 27, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 27, 2026, 5:23 PM EDT